Related Searches : Deslorelin AcetateacetateAcetate filmCHROMIUM ACETATEAcetate ScrewdriverCobalt Acetate

Deslorelin acetate

  • USD 1 - 100 / Gram  
  • 10 Gram/Grams
  • Pharmaceutical Grade
  • 3-5 days afer your payment
  • CAS 57773-65-6
  • Keep in cool dry and dark place
  • Tag:Deslorelin acetate
  • Supplier - Shenzhen Simeiquan BioChemical Tech Co.ltd
  • China (Mainland)China (Mainland)
  • US$10 Million - US$50 Million
  • Above 1000 People
  • Manufacturer
  • North America,South America,Eastern Europe,Southeast Asia,Africa,Oceania,Mid East,Eastern Asia,Western Europe
  •     
  • skype
  • Ms.Yi
  • 86-027-50755960
Post Date : August 01
Product Details
Company Profile

Item specifics

Pharmaceutical Grade
3-5 days afer your payment
CAS 57773-65-6
Keep in cool dry and dark place
Western Union, Money gram, T/T
Deslorelin acetate
Auxiliaries and Other Medicinal Chemicals
bella.lee36
C98H138N24O33
99%
China (Mainland),Hubei
White crystalline powder
Discreet Package as your requirement
smile2bella@ycphar.com
57773-65-6
Medicine Grade
YC

Specifications

CAS 57773-65-6 Deslorelin acetate

99% Polypeptide Hormones Deslorelin AcetateCAS 57773-65-6 For The Initial Flare Effect Upon The Pituitary

Deslorelin Acetate

Sequence : Glp-His-Trp-Ser-Tyr-D-Trp-Leu-Arg-Pro-NHEt

Cas No. : 57773-65-6

Molecular Formula : C64H83N17O12

Molecular Weight : 1282.47

Purity (HPLC) : 99.0%min.

Appearance : White powder

Single Impurity (HPLC) : 0.5%max

Amino Acid Composition : ±10% of theoretical

Peptide Content (N%) : ≥80.0%

Water Content (Karl Fischer) : ≤8.0%

Acetate Content (HPIC) : ≤12.0%

MS (ESI) : Consistent

Mass Balance : 95.0~105.0%

Grade : Pharmaceutical Grade

Storage: Closed, below 2 ~ 8°C preservation

Usage : Deslorelin is primarily used for the initial flare effect upon the pituitary, and its associated surge of LH secretion.

Deslorelin acetate is an injectable gonadotropin releasing hormone super-agonist (GnRH agonist) also known as an LHRH agonist. It stops the production of sex hormones (testosterone and oestrogen).

Deslorelin Acetate is marketed by Peptech with the brand name Ovuplant. It is currently approved for use in veterinary medicine and is used to induce ovulation in mares as part of the artificial insemination process. It is also used to stabilize high-risk pregnancies, mainly of livestock. Unlike other GnRH agonists, which are mainly used to inhibit luteinizing hormone and follicle-stimulating hormone by their ultimate downregulation of the pituitary gland, Deslorelin is primarily used for the initial flare effect upon the pituitary, and its associated surge of LH secretion.

Application:

Deslorelin was successfully trialed in the US and was approved for veterinary use under certain circumstances. In Europe, it was approved for use in equine assisted reproduction.

It is also being trialed in humans to study its efficacy in treatment of breast cancer in women,and in treating precocious puberty and congenital adrenal hyperplasia in male and female children.

Company Related ProductsView the Seller's Products
Bivalirudin

Bivalirudin

Bivalirudin

CAS 128270-60-0 Bivalirudin Trifluoroacetate

98% Injectable Polypeptide Hormones Bivalirudin Trifluoroacetate CAS 128270-60-0 Bivalirudin For Inhibiting Thrombin-mediated Platelet Activation & Aggregation

Bivalirudin Trifluoroacetate

Sequence:D-Phe-Pro-Arg-Pro-Gly-Gly-Gly-Gly-Asn-Gly-Asp-Phe-Glu-Glu-Ile-Pro-Glu-Glu-Tyr-Leu-OH

Alias:Angiomax;Bivalirudin;Hirulog

Cas No.: 128270-60-0

Molecular Formula: C98H138N24O33

Molecular Weight: 2180.29

Purity (HPLC): 98.0%min.

Appearance: White Powder

Single Impurity (HPLC): 1.0%max

Amino Acid Composition: ±10% of theoretical

Peptide Content (N%): >80.0%

Water Content (Karl Fischer): <8.0%

TrifluoroAcetate Content(HPIC): >12.0%

MS (ESI): Consistent

Mass Balance: 95.0~105.0%

Grade : Pharmaceutical Grade

Storage: Closed, below 2 ~ 8°C preservation

Usage : This product is mainly used for the prevention of vascular forming interventional therapy in the treatment of unstable angina, ischemic complications before and after.It inhibits both circulating and clot-bound thrombin, while also inhibiting thrombin-mediated platelet activation and aggregation.

Description:

Bivalirudin (Angiomax or Angiox, manufactured by The Medicines Company) is a specific and reversible direct thrombin inhibitor (DTI).

Bivalirudin is a DTI that overcomes many limitations seen with indirect thrombin inhibitors, such as heparin. Bivalirudin is a short, synthetic peptide that is potent, highly specific, and a reversible inhibitor of thrombin. It inhibits both circulating and clot-bound thrombin, while also inhibiting thrombin-mediated platelet activation and aggregation. Bivalirudin has a quick onset of action and a short half-life. It does not bind to plasma proteins (other than thrombin) or to red blood cells. Therefore it has a predictable antithrombotic response. There is no risk for Heparin Induced Thrombocytopenia/Heparin Induced Thrombosis-Thrombocytopenia Syndrome (HIT/HITTS). It does not require a binding cofactor such as antithrombin and does not activate platelets. These characteristics make bivalirudin an ideal alternative to heparin.

Bivalirudin clinical studies demonstrated consistent positive outcomes in patients with stable angina, unstable angina (UA), non-ST segment elevation myocardial infarction (NSTEMI), and ST-segment elevation myocardial infarction (STEMI) undergoing PCI in 7 major randomized trials

Application:

Bivalirudin is indicated for use as an anticoagulant in patients with unstable angina undergoing percutaneous transluminal coronary angioplasty (PTCA).

Bivalirudin with provisional use of glycoprotein IIb/IIIa inhibitor (GPI) is indicated for use as an anticoagulant in patients undergoing percutaneous coronary intervention (PCI).

Bivalirudin is indicated for patients with, or at risk of HIT/HITTS undergoing PCI.

Bivalirudin is intended for use with aspirin and has been studied only in patients receiving concomitant aspirin.

Detail more >>
Bivalirudin Trifluoroacetate

Bivalirudin Trifluoroacetate

Bivalirudin Trifluoroacetate

CAS 128270-60-0 Bivalirudin

98% Injectable Polypeptide Hormones Bivalirudin Trifluoroacetate CAS 128270-60-0 Bivalirudin For Inhibiting Thrombin-mediated Platelet Activation & Aggregation

Bivalirudin Trifluoroacetate

Sequence:D-Phe-Pro-Arg-Pro-Gly-Gly-Gly-Gly-Asn-Gly-Asp-Phe-Glu-Glu-Ile-Pro-Glu-Glu-Tyr-Leu-OH

Alias:Angiomax;Bivalirudin;Hirulog

Cas No.: 128270-60-0

Molecular Formula: C98H138N24O33

Molecular Weight: 2180.29

Purity (HPLC): 98.0%min.

Appearance: White Powder

Single Impurity (HPLC): 1.0%max

Amino Acid Composition: ±10% of theoretical

Peptide Content (N%): >80.0%

Water Content (Karl Fischer): <8.0%

TrifluoroAcetate Content(HPIC): >12.0%

MS (ESI): Consistent

Mass Balance: 95.0~105.0%

Grade : Pharmaceutical Grade

Storage: Closed, below 2 ~ 8°C preservation

Usage : This product is mainly used for the prevention of vascular forming interventional therapy in the treatment of unstable angina, ischemic complications before and after.It inhibits both circulating and clot-bound thrombin, while also inhibiting thrombin-mediated platelet activation and aggregation.

Description:

Bivalirudin (Angiomax or Angiox, manufactured by The Medicines Company) is a specific and reversible direct thrombin inhibitor (DTI).

Bivalirudin is a DTI that overcomes many limitations seen with indirect thrombin inhibitors, such as heparin. Bivalirudin is a short, synthetic peptide that is potent, highly specific, and a reversible inhibitor of thrombin. It inhibits both circulating and clot-bound thrombin, while also inhibiting thrombin-mediated platelet activation and aggregation. Bivalirudin has a quick onset of action and a short half-life. It does not bind to plasma proteins (other than thrombin) or to red blood cells. Therefore it has a predictable antithrombotic response. There is no risk for Heparin Induced Thrombocytopenia/Heparin Induced Thrombosis-Thrombocytopenia Syndrome (HIT/HITTS). It does not require a binding cofactor such as antithrombin and does not activate platelets. These characteristics make bivalirudin an ideal alternative to heparin.

Bivalirudin clinical studies demonstrated consistent positive outcomes in patients with stable angina, unstable angina (UA), non-ST segment elevation myocardial infarction (NSTEMI), and ST-segment elevation myocardial infarction (STEMI) undergoing PCI in 7 major randomized trials

Application:

Bivalirudin is indicated for use as an anticoagulant in patients with unstable angina undergoing percutaneous transluminal coronary angioplasty (PTCA).

Bivalirudin with provisional use of glycoprotein IIb/IIIa inhibitor (GPI) is indicated for use as an anticoagulant in patients undergoing percutaneous coronary intervention (PCI).

Bivalirudin is indicated for patients with, or at risk of HIT/HITTS undergoing PCI.

Bivalirudin is intended for use with aspirin and has been studied only in patients receiving concomitant aspirin.

Detail more >>
You may also be interested in:Hydrocortisone Acetateprednisone acetatebenzyl acetateammonium acetateManganese AcetateAcetate Boxes
The informations displayed above are provided by the seller. The authenticity, accuracy and legality of the content are borne by the seller. Please realize that the risks in Internet transactions are objective.
Talk with SupplierX
Jeana Yi:
Can I help you?
Contact Supplier

Selected(1/4)Contact or Compare